Dirithromycin

Dirithromycin (LY237216), a derivative of Erythromycin, is a potent and orally active semi-synthetic macrolide antibiotic. Dirithromycin is active against gram-positive bacteria, Legionella spp., Helicobacter pylori, and Chlamydia trachomatis[1][2].

Product Specifications

CAS Number

[62013-04-1]

Product Name Alternative

LY237216

UNSPSC

12352005

Hazard Statement

H317

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/dirithromycin.html

Purity

98.0

Solubility

DMSO : 33.33 mg/mL (ultrasonic) |Ethanol : ≥ 50 mg/mL

Smiles

CC1[C@@]([C@](O)([C@H](OC([C@@H]2C)=O)CC)C)([H])O[C@H](COCCOC)N[C@@]1([H])[C@](C[C@@](O)([C@@H]([C@@H](C)[C@]2([H])O[C@@](O[C@@H](C)[C@@H]3O)([H])C[C@@]3(C)OC)O[C@@](O[C@H](C)C[C@@H]4N(C)C)([H])[C@@H]4O)C)([H])C

Molecular Formula

C42H78N2O14

Molecular Weight

835.07

Precautions

H317

References & Citations

[1]Wasilewski MM, et, al. Five-day dirithromycin therapy is as effective as seven-day erythromycin therapy for acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1999 Apr;43 (4) :541-8.|[2]Counter FT, et, al. Synthesis and antimicrobial evaluation of dirithromycin (AS-E 136; LY237216), a new macrolide antibiotic derived from erythromycin. Antimicrob Agents Chemother. 1991 Jun;35 (6) :1116-26.